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Elevated serum ferritin levels occur due to iron overload or during inflammation
and macrophage activation. A correlation of high serum ferritin levels with increased
mortality after alloSCT has been suggested by several retrospective analyses as well
as by two smaller prospective studies. This prospective multicentric study aimed to
study the association of ferritin serum levels before start of conditioning with alloSCT
outcome. Patients with acute leukemia, lymphoma or MDS receiving a matched sibling
alloSCT for the first time were considered for inclusion, regardless of conditioning.
A comparison of outcomes between patients with high and low ferritin level was
performed using univariate analysis and multivariate analysis using cause-specific Cox
model. Twenty centers reported data on 298 alloSCT recipients. The ferritin cut off point
was determined at 1500 µg/l (median of measured ferritin levels). In alloSCT recipients
with ferritin levels above cut off measured before the start of conditioning, overall survival
(HR = 2.5, CI = 1.5–4.1, p = 0.0005) and progression-free survival (HR = 2.4, CI = 1.6–
3.8, p < 0.0001) were inferior. Excess mortality in the high ferritin group was due to both
higher relapse incidence (HR = 2.2, CI = 1.2–3.8, p = 0.007) and increased non-relapse
mortality (NRM) (HR = 3.1, CI = 1.5–6.4, p = 0.002). NRM was driven by significantly
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higher infection-related mortality in the high ferritin group (HR = 3.9, CI = 1.6–9.7,
p = 0.003). Acute and chronic GVHD incidence or severity were not associated to serum
ferritin levels. We conclude that ferritin levels can serve as routine laboratory biomarker
for mortality risk assessment before alloSCT.
Keywords: transplantation, stem cell, immunology, biomarker, iron metabolism, ferritin
INTRODUCTION
Allogeneic stem cell transplantation (alloSCT) is a curative
treatment option for patients suffering from hematological
malignancies and some other diseases. High treatment-associated
mortality is a major difficulty of this procedure and predicting
mortality is a clinical challenge. The current standard for alloSCT
risk assessment is the use of clinical scores, such as the European
Society for Blood and Marrow Transplantation (EBMT)-score
(1), the Hematopoietic Cell Transplantation-Comorbidity Index
(HCT-CI) (2), the Dana-Farber Cancer Institute (DFCI)-score
(3), and a combination of such scores (4).
The use of biomarkers to further improve alloSCT risk
assessment is an attractive option (5). Mortality in the first
months/years after alloSCT is mainly due to leukemia relapse,
infections or graft-versus-host disease (GVHD). In all these
clinical situations serum ferritin, an acute phase and iron binding
protein, has been demonstrated to be elevated (6–13). Based on
this background results, several retrospective studies and meta-
analyses have suggested that serum ferritin may be of use as a
biomarker during alloSCT (7, 14–18).
Based on these preliminary results and on the fact that
ferritin is a routine laboratory parameter assessed in patients
undergoing alloSCT, we saw a strong rationale for investigating
serum ferritin as a biomarker. The Transplant Complications
Working Party (TCWP) of the EBMT performed a prospective,
multicenter and non-interventional study to test whether the
ferritin level evaluated prior to the start of conditioning therapy is
an independent risk factor for increased mortality after alloSCT.
MATERIALS AND METHODS
Data Source, Study Design, and Data
Collection
We asked EBMT centers performing more than 50 alloSCT
per year if they were willing to participate in this prospective
study. Twenty centers in ten countries agreed to participate.
Data collection for the EBMT registry was approved by the
European Society for Blood and Marrow Transplantation and by
the IRB of Charité Universitätsmedizin Berlin as well as by IRBs
of the participating centers. Data were prospectively collected
between 8/2014 and 2/2018. Consecutive alloSCT recipients with
acute leukemia, lymphoma or myelodysplastic syndrome (MDS)
receiving a first matched sibling alloSCT from peripheral blood,
regardless of conditioning, were eligible, provided they had
signed an informed consent document that permitted sharing
of clinical data according to national rules. Basic data on
patient and disease characteristics as well as longer term follow
up was taken from minimal essential data (MED-A) forms,
which are submitted from all consecutive patients to the central
EBMT registry. In addition, we designed registration and MED-
B/C forms that were prospectively collected and specific to
this study. Treatment teams completed specific forms (MED-
B/C) forms at the time of registration and at day + 100 after
alloSCT. The MED-B/C form contained detailed information
on ferritin serum levels prior to alloSCT, patient characteristics,
infectious- as well as non-infectious complications, GVHD
staging, morbidity and mortality. Ferritin levels were determined




Patient, disease, and transplant-related characteristics for the two
cohorts (ferritin levels prior to alloSCT above median/ferritin
levels below median) were compared by using χ2 statistics for
categorical variables and the Mann-Whitney test for continuous
variables. Primary endpoint was the incidence of acute GVHD.
Acute GVHD was picked as a primary endpoint because of
our previous observation on a correlation of maximum Ferritin
levels after alloSCT with acute GVHD severity (12). Secondary
endpoints were relapse incidence (RI), non-relapse mortality
(NRM), overall survival (OS), progression free survival (PFS),
and the incidence of chronic GVHD. PFS was defined as
survival with no evidence of relapse or progression. RI was
defined as the probability of having had a relapse during
follow up time. Death without experiencing a relapse was
a competing event. NRM was defined as death without
evidence of relapse or progression. OS was defined as the
time from alloSCT to death, regardless of the cause. To
define acute GVHD during the consensus process, we used
the criteria established by the MAGIC group (19–21). To
define chronic GVHD, we used the NIH 2014 criteria (20–
22). Cumulative incidence was used to estimate the endpoints
of NRM, RI, acute, and chronic GVHD to accommodate
for competing risks. To study acute and chronic GVHD,
we considered relapse and death to be competing events.
Probabilities of OS and PFS were calculated using the Kaplan–
Meier method. Univariate analyses were done using the Gray
test for cumulative incidence functions and the log rank
test for OS and PFS. A Cox proportional hazards model
was used for multivariate regression. All variables differing
significantly between the 2 groups or factors associated with
one outcome in univariate analysis were included in the
Cox model. The following variables entered the multivariate
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models as possible confounders: age, sex mismatch between
recipient and donor, diagnosis, disease status, Karnofsky score,
number of CD34 cells given, intensity of conditioning (EBMT
definition: myeloablative conditioning (MAC) was defined as
TBI > 6 gray or oral busulfan > 8 mg/kg or intravenous
busulfan > 6.4 mg/kg), type of GVHD prophylaxis, ATG use,
time from diagnosis to transplant, year of transplant and CMV
status. As the number of variables was too high regarding the
number of events, a stepwise selection using Akaike information
criterion (AIC) was run for all the confounding factors. The
difference between the two cohorts was then assessed in the
final selected model.
Results were expressed as the hazard ratio (HR) with
the 95% confidence interval (95% CI). Proportional hazards
assumptions were checked systematically for all proposed
models using the Grambsch-Therneau residual-based
test. All tests were 2-sided. The type I error rate was
fixed at 0.05 for the determination of factors associated
with time-to-event outcomes. Statistical analyses were
performed in November 2018 with R 3.4.2 (R Core Team
(2017). R: A language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna,
Austria1).
RESULTS
Patients and Transplant Characteristics
The entry criteria for analysis of OS were fulfilled in 298
patients. The main patients and transplant characteristics that
were included in the analysis of OS are described in Table 1. Most
parameters were balanced between the two cohorts. However, a
higher percentage of sex mismatch transplants in the direction
of female to male were observed in the group of patients with
ferritin above cut off before alloSCT. The ferritin cut off point was
determined at 1500 µg/l (median of measured ferritin levels).
Endpoints
In the present study, the incidence of acute GVHD grades
II–IV and grades III–IV in the whole population at
1https://www.R-project.org/
TABLE 1 | Population characteristics.
Ferritin <=1500 µ G/L (N = 153) Ferritin > 1500 µ G/L (N = 145) P-value
Year of transplant median (range) [IQR] 2016 (2014–2018)[2015–2017] 2015 (2014–2018)[2015–2016] 0.6
Patient age (years) Median (range) [IQR] 52 (17.1–71.3) [38.1–60.2] 53.2 (19–70.9) [42.9–62.3] 0.3
Time from diagnosis to transplant (months) median (range) [IQR] 5 (1–71) [3–8] 4 (1–61) [3–6] 0.05
Number of CD34 + cells infused (E + 06) median (range) [IQR] 5.9 (0.9–10.7) [4.5–7.2] 5.5 (0.6–10.2) [4.2–6.7] 0.1
Sex mismatch 0.012
Female to male 27 (18%) 43 (30%)
Other combination 123 (82%) 98 (70%)
Diagnosis 0.058
Acute leukemia 93 (61%) 107 (74%)
Lymphoma 19 (12%) 12 (8%)
MDS 41 (27%) 26 (18%)
Disease status 0.2
CR 94 (64%) 98 (70%)
Not in CR 54 (36%) 42 (30%)
ATG 0.5
No 77 (50%) 79 (54%)
Yes 76 (50%) 66 (46%)
Conditioning intensity 0.9
MAC/CHEMO 30 (20%) 32 (22%)
MAC/TBI 26 (17%) 25 (17%)
RIC 95 (63%) 87 (61%)
Karnovsky Score 0.8
< = 80 23 (16%) 21 (15%)
90–100 125 (85%) 122 (85%)
Missing 5 2
Disease risk index 0.8
Low 6 (4%) 4 (3%)
Intermediate 86 (59%) 88 (65%)
High 48 (33%) 39 (29%)
Very high 5 (3%) 5 (4%)
Missing 8 9
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FIGURE 1 | Survival after alloSCT in both cohorts according to ferritin serum levels prior to alloSCT. Overall survival (OS) (A) as well as progression free survival (PFS)
(B) were significantly inferior in patients with high ferritin serum levels (blue line) as compared to patients with low ferritin levels (red line).
FIGURE 2 | Relapse incidence (RI) after alloSCT in both cohorts according to ferritin serum levels prior to alloSCT. Relapse incidence was increased in patients with
high ferritin serum levels (blue line) as compared to patients with low ferritin levels (red line).
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FIGURE 3 | Non-relapse mortality (NRM) after alloSCT in both cohorts according to ferritin serum levels prior to alloSCT. NRM was increased in patients with high
ferritin serum levels (blue line) as compared to patients with low ferritin levels (red line).
100 days was 25% and 11%, respectively. The incidence of
chronic GVHD and severe chronic GVHD at last follow
up was 25.8% and 15.1%, respectively. We observed no
differences in incidence and severity of acute GVHD as
well as chronic GVHD in between the two cohorts. As
expected, chronic GVHD incidence was significantly lower
in alloSCT recipients receiving anti-T-cell globulin as part of
the conditioning regimen (ATG, HR = 0.25, CI = 0.13–0.5,
p < 0.0001).
We found that OS and PFS of alloSCT recipients with ferritin
levels above cut off measured before start of conditioning were
significantly shorter as compared with the low ferritin cohort
(Figure 1A, OS univariate HR = 2.3, CI = 1.4–3.6, p = 0.00041;
multivariate HR = 2.5, CI = 1.5–4.1, p = 0.0005) (Figure 1B,
PFS univariate HR = 2.1, CI = 1.4–3.2, p = 0.00014; multivariate
HR = 2.4, CI = 1.6–3.8, p < 0.0001).
Mortality was 29% at last follow up and with distribution of
15.0% relapse/progression as well as 14% NRM. Excess mortality
in the high ferritin group was driven by higher relapse incidence
as well as by higher NRM. We found that the incidence of
relapse after alloSCT was 24.2% till the end of follow up. AlloSCT
recipients with ferritin levels above cut off had significantly more
relapses as compared with the low ferritin group (Figure 2,
univariate HR = 1.7, CI = 1–2.8, p = 0.03; multivariate HR = 2.2,
CI = 1.2–3.8, p = 0.007).
Patients in the ferritin high group had significantly more
NRM (Figure 3, univariate HR = 3.1, CI = 1.5–6.3, p = 0.002;
multivariate HR = 3.1, CI = 1.5–6.4, p = 0.002). NRM was
driven by significantly higher infection-related mortality in the
high ferritin group (Figure 4, univariate HR = 3.9, CI = 1.6–
9.7, p = 0.003; multivariate HR = 3.9, CI = 1.6–9.7, p = 0.003).
A descriptive analysis of causes of death is given in Table 2.
We conclude that serum ferritin levels prior to alloSCT are an
independent risk factor for OS, relapse, and NRM at one year.
DISCUSSION
Our results from this prospective study indicate that serum
ferritin prior to alloSCT is associated to mortality after alloSCT.
This trial served as confirmation of previous retrospective
studies, which delivered preliminary results pointing in the same
direction (7, 14–18). Of note, the Center for International Blood
and Marrow Transplantation Research (CIBMTR) published an
evaluation on different biomarkers and found that ferritin levels
above 2500µg/ml were not associated with inferior alloSCT
outcome (23) contrasting previously published studies (7, 14–18)
and our results.
A limitation of our clinical study is the lack of mechanistic
insight on the role of ferritin in development of complications
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FIGURE 4 | Infection-related mortality after alloSCT in both cohorts according to ferritin serum levels prior to alloSCT. Infection-related mortality was increased in
patients with high ferritin serum levels (blue line) as compared to patients with low ferritin levels (red line).
TABLE 2 | Mortality and cause of death in both cohorts.
Status at last follow up Ferritin <= 1500 µ
G/L (N = 153)
Ferritin > 1500 µ G/L
(N = 145)
Alive 126 (82%) 92 (63%)
Dead 26 (18%) 53 (37%)
Death due to relapse or
progression
15 (10%) 27 (19%)
Death without relapse 11 (7%) 26 (18%)
NRM infection related 5 (3%) 14 (10%)
NRM due to other causes 6 (4%) 12 (8%)
after alloSCT. In addition, our patient population was restricted
to alloSCT from HLA-identical sibling donors. We are therefore
unable to draw definite conclusions from these results regarding
the association of ferritin levels with outcome in matched
unrelated donor alloSCT or in haploidentical alloSCT, which are
increasingly used.
An attractive feature of using ferritin as a biomarker
for alloSCT outcome is that many severe clinical conditions
occurring in the peri-transplant period are associated to high
ferritin levels. First, high ferritin is related to iron overload
although those factors are not always closely associated (10).
Iron overload due to multiple pre-transplant red blood cell
transfusion has been described to have negative impact on
alloSCT outcome (7, 8, 11, 13). Second, ferritin levels are
very high during severe graft-versus-host disease and during
macrophage activation syndromes after alloSCT (12). Third,
ferritin is an acute phase protein that is regularly elevated
during acute and chronic infections (24, 25). Ferritin has
been implicated in fungal growth and high ferritin levels have
previously been suggested to be a risk factor for infections
after alloSCT (26–28). In line with these data, our results
indicated increased infection-related mortality in the group
with higher ferritin levels. Fourth, ferritin levels have been
associated with increased growth of acute myeloid leukemia
(AML) (9, 16). So, taken together ferritin is elevated during
tumor relapse and major infectious as well as non-infectious
complications after alloSCT. Based on these considerations,
ferritin might be a surrogate marker for organ dysfunction
and it is understandable that it can serve as a biomarker
for alloSCT mortality with significant prediction of tumor
relapses as well as NRM.
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In our study ferritin levels were not associated to a higher
disease stage (CR/non-CR) or a longer time between diagnosis
and alloSCT. In line with these findings, high ferritin levels
were not associated to the diagnosis of MDS, where patients
often receive multiple blood transfusions prior to alloSCT. There
are two likely explanations: (1) Patients with multiple blood
transfusions often receive drug treatment to reduce iron overload,
and (2) The ferritin levels may not primarily reflect iron overload
as discussed in the previous paragraph. Interestingly, a recent
prospective study in patients with MDS and CMML undergoing
alloSCT reported that administration of iron chelation therapy
prior to HSCT was not associated to outcome. However, early
iron reduction after alloSCT (started before d + 180) was
associated to improved relapse free survival (29).
In conclusion, we found that high serum ferritin is an
independent risk factor for increased mortality after alloSCT. The
perspective of the future use of ferritin as biomarker will be likely
a combination with clinical parameters such as the EBMT-score
or the HCT-CI. However, to investigate such a combination or
a combination with alternative biomarkers was not within the
scope of our study and remains to be analyzed in the future.
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